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Introduction
Transplantation research has provided many insights
into fundamental aspects of immunology, including the
biology of dendritic cells (DCs). The critical tools of
transplantation research—antibodies to major histocompatibility complex (MHC) class I and II products, the
mixed leukocyte reaction (MLR), and rodent experimental models of skin and organ transplantation—were vital
to the initial characterization of DCs as distinct leukocytes, specialized to initiate graft rejection (reviewed in
Steinman, 1991). It was proposed that bone marrow–
derived DCs in the allograft were the foes responsible
for immunogenicity. An oversimplified concept arose
that DC elimination, something that is very difficult to
achieve, would lead to graft acceptance. In fact, the
situation is far more complicated. DCs in both the graft
donor and the recipient can act as the foe, stimulating
rejection by what are termed the direct and indirect
pathways, respectively. However, there is also emerging
evidence that DCs can act as a friend, promoting graft
acceptance. More broadly, the studies of DCs in transplantation are valuable for understanding their role in
immunity to other antigens and, recently, in peripheral
tolerance. This review addresses some potential roles of
DCs in transplantation in the light of current knowledge
concerning DC biology, immunity to alloantigens, and
peripheral T cell tolerance.
Some Features of DCs
DCs were first distinguished from other white blood cells
on the basis of their distinctive cell shape and an absence of critical lymphocyte and phagocyte properties.
When these criteria were used to enrich DCs from different tissue sources, a high level of antigen-presenting
MHC products, especially MHC class II (⬎106 molecules/
cell when measured), was always noted. The capacity
of T cells to respond to MHC products on DCs was
tested in the MLR. The DCs proved to be remarkably
potent, at least 100 times more active than MHC class
II–bearing macrophages and B cells. Indeed, the MLR
‡ To whom correspondence should be addressed (e-mail: r.lechler@
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had to be renamed from mixed lymphocyte to mixed
leukocyte reaction because MHC class II–bearing B cells
from mouse spleen or from human blood were weak or
inactive in stimulating the MLR. Purified CD4⫹ and CD8⫹
T cells each could be stimulated directly by the DCs,
and this stimulation occurred in discrete cell aggregates
in which the T cells began to grow while in contact with
the DCs. Once activated T cells were produced, the T
blasts responded vigorously to other allogeneic cells,
such as B cells and macrophages. In other words, antigen presentation on either MHC class I or II in the MLR
was occurring in two phases: in the “afferent” phase,
DCs stimulated the growth and differentiation of CD4⫹
and CD8⫹ alloreactive T cells, while, in the “efferent”
phase, the activated T cells responded to other types
of antigen-presenting cells (APC) in an allogeneic MHCspecific manner. The same two stages in cell-mediated
immunity were also observed in responses to nominal
antigens, particularly in the induction of the primary antibody response (reviewed in Steinman, 1991).
Strong staining for MHC class II and an absence of
B cell or macrophage markers were used to search for
DCs in situ. In tissue sections from rats and humans,
MHC class II–positive DCs were identified in the interstitial spaces of all organs examined except the brain parenchyma. In lymphoid tissues, DCs are abundant in the
T cell areas of spleen and lymph nodes and the medulla
of the thymus. The same criteria were used to identify
DCs in human blood and in afferent lymph from many
species, but DCs were absent in efferent lymph. When
isolated DCs were reinfused into rodents, the DCs migrated to the T cell areas of the draining lymphoid organ.
After antigen administration by intramuscular or intravenous routes, the DCs in the lymph and spleen were the
main cell type able to present antigen to T cells. The
concept arose that DCs could pick up antigens in the
periphery and migrate to the T cell areas (in spleen via
the blood, in lymph nodes via the lymph), where they
could either initiate an immune response to the antigens
that the DCs were presenting or simply die (Figure 1).
As we will consider below, death is followed by re-presentation of proteins in the dying DCs by resident DC
in the lymph node. In transplant models, DCs derived
from transplanted allogeneic tissues and carrying donor
MHC antigens could be identified in the peripheral
lymphoid tissues of graft recipients. Further, many studies with nominal antigens showed that injections of antigen-charged DCs initiated T cell–mediated immunity,
including protective antimicrobial and antitumor immunity. When tested, the T cell response was restricted to
antigens presented by the MHC products of the injected
DCs and not to the recipient’s antigen-presenting cells,
indicating that DCs could directly stimulate recipient T
cells. In sum, the distribution and migration of DCs in
vivo (Figure 1) correlated closely with their capacity to
mediate the afferent phase of cell-mediated immunity
(reviewed in Steinman, 1991).
DCs are continuously produced in the bone marrow,
undergoing considerable turnover in most tissues except the epidermis. Immature DCs and their precursors
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Figure 1. Distribution and Migration of Dendritic Cells
(1) Proliferating DC progenitors in the bone marrow release precursor and immature forms of DC into the blood.
(2) Precursors to DC in the blood migrate to peripheral tissues.
(3) Immature DC capture pathogens and self-antigens from the tissue.
(4) Antigen-loaded DC enter afferent lymphatics or the blood and thereby migrate to secondary lymphoid tissue; this process may be
accompanied by maturation upon receipt of appropriate stimuli.
(5) Tissue DC present MHC-peptide (black circles) complexes to antigen-specific T cells in the secondary lymphoid organs.

are always trafficking through tissues in the steady state,
in the absence of infection or inflammation, and then
dying in the lymphoid organs. In the airways, for example, DCs have a half-life of ⬍2 days (Holt et al., 1994).
When afferent lymphatics have been cannulated in the
limbs of sheep and humans, a flux of several thousand
DCs per hour is noted, as is also the case with other
lymphatics in rodents. Recent studies of the turnover of
DCs in lymphoid tissues reveal half-lives of 1.5–3 days
(Kamath et al., 2000)—even faster than the earliest measurements on the life span of these cells. Beyond the
bone marrow, several possibly distinct sources of DCs
are found in the blood (Table 1). However, the continued
production and traffic of DCs in the steady state are not
really analogous to granulocytes, which are constantly

being produced just in case infection should arise.
Rather, DCs in the steady state may have a second
role—transporting antigens from the periphery for the
purpose of inducing and/or maintaining peripheral tolerance in the draining lymph node (Kurts et al., 1997a;
Huang et al., 2000). This will be discussed in more detail
below.
The mechanisms underlying the immunogenicity of
DCs are beginning to be unravelled. The DCs in blood
and tissues prove to be immature, not fully differentiated
to act as potent stimulators of immunity. The first example was the Langerhans cell in the epidermis (Schuler
and Steinman, 1985). Immature DCs can capture soluble
and particulate antigens, especially by receptor-mediated pathways. Their MHC class II products lie primarily

Table 1. Bone Marrow–Derived Dendritic Cell Precursors in the Blood
Precursors

Stimuli for DC Development

Monocytes (CD14⫹, CD11c⫹)

GM-CSF and IL-4 followed by maturation stimuli
(TNF, IL-1, CD40L, LPS, CpG oligos, necrosis)
reverse migration across endothelia, possibly lymphatics
particle uptake during inflammation
enveloped viruses
CD40L and IL-3
CpG oligos
inflammatory cytokines
infection
CpG oligos

Plasmacytoid cells (CD14⫺, CD11c⫺)

Immature DCs and Langerhans cells
(CD14⫺, CD11c⫹)
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within MHC class II–positive endocytic vacuoles that
also contain HLA-DM molecules, which facilitate the
binding of high-affinity peptides. During maturation,
MHC peptide complexes begin to form within the MHC
class II– and HLA-DM-positive compartments, followed
by transport in nonlysosomal vesicles to the cell surface
in large amounts (Pierre et al., 1997). Several costimulatory molecules are also expressed, with especially high
levels of CD86. The MHC-peptide complexes are found
in clusters at the DC surface together with CD86 (Turley
et al., 2000). It is postulated that these high levels of
antigen-presenting and costimulatory molecules, in a
clustered distribution, initiate the formation of the immunologic synapse, bringing together essential elements,
like the T cell receptor (TCR) and CD28, that are required
for T cell activation. Furthermore, mature DCs cease
many of their endocytic activities, most likely accounting
for the longevity of MHC-peptide complexes at the cell
surface. Maturing DCs change in many other ways, including the production of cytokines like IL-12 and a
reshaping of their chemokine receptors, the latter contributing to their migration to the T cell areas of lymphoid
tissue (Cyster, 1999; Sallusto and Lanzavecchia, 1999).
Multidrug transporters, by pumping cysteinyl leukotrienes, are newly recognized intermediaries for DC maturation and migration in vivo (Robbiani et al., 2000).
Maturation stimuli for DC development comprise inflammatory cytokines (TNF␣, IL-1), microbial products
(LPS, CpG deoxyoligonucleotides), and CD40L on activated T cells, platelets, and mast cells. Many of these
maturation stimuli act on receptors that trigger NF-B
activation via the TNF receptor–associated factor TRAF
6. Receptors for maturation include IL-1R, TNF-R family
members, and Toll receptors or TLRs. However, the act
of transplantation itself appears to trigger the maturation
and migration of DCs (Larsen et al., 1990), although
the responsible stimuli are not yet known. CD40 is an
intriguing player, since, in CD40L knockout mice, DCs
are unable to migrate during contact allergy, another
powerful T cell response in which DCs also mature and
migrate to draining lymph nodes. In both transplantation
(Barker and Billingham, 1968) and contact allergy (Frey
and Wenk, 1957), the severing of afferent lymphatics
reduces sensitization in response to skin grafts and allergens, suggesting that DC traffic is critical for immunization. Studies in corneal transplantation lend further
support to these concepts, in that the likelihood of corneal allograft rejection was observed to correlate with
the DC content of the transplanted tissue (Niederkorn,
1999). In addition, TNF mRNA was induced, even in
syngeneic grafts, due to the trauma of surgery, providing
a maturation signal for local DCs (King et al., 2000).
In summary, DCs are centrally involved in the initiation
of T cell–dependent immune responses, such as transplant rejection. The roles of donor and recipient DCs
and their contributions to sensitization and to the induction of tolerance in the two pathways of allorecognition
are discussed separately below.
Contributions of Direct and Indirect Pathways of
Anti-MHC Allorecognition to Transplant Rejection
The Direct Pathway
MHC alloantigens can be recognized by T cells via two
distinct pathways, and DCs are likely to be central to

both. The recognition events that lead to the vigor of
responses observed when MHC-incompatible cells are
cocultured are referred to as the “direct” pathway of
allorecognition. This involves the ligation of T cell receptors on alloreactive T cells by foreign MHC molecules,
intact, on the surface of allogeneic cells. It was noted
several decades ago that underlying this strength of
proliferative response was a uniquely high frequency of
T cells with direct allospecificity. Evidence from a variety
of sources, including a recent structural analysis of an
alloreactive TCR (Daniel et al., 1998), indicates that this
mode of allorecognition results from cross-reactivity by
T cells specific for a self-MHC molecule, “A,” with peptide “x” on an allogeneic MHC molecule, “B,” with peptide “y.” At face value, the recognition of allogeneic MHC
breaks the rules of thymic positive selection for selfMHC restriction. However, the structural similarity between the TCR contact surfaces of many MHC alleles
allows a substantial fraction of direct alloresponses to
be accommodated within the framework of positive selection. In responder–stimulator combinations in which
such structural similarities apply, allorecognition can be
regarded as mimicking self-MHC restriction and as directed against novel peptides that are bound by the
allogeneic but not the self-MHC molecules due to differences in the peptide binding groove (Lechler et al., 1990).
In combinations in which there are multiple amino acid
differences in the TCR contact surfaces, the alloresponse is likely to result from a chance higher affinity
cross-reaction with the foreign MHC structure. Given
the bias that appears to exist in TCR genes for MHC
recognition (Merkenschlager et al., 1997), this is likely
to occur in structurally dissimilar responder–stimulator
combinations with sufficient frequency to account for
the numbers of alloreactive T cells identified by limiting
dilution analysis assays.
It has long been assumed that acute transplant rejection represents the in vivo correlate of the in vitro MLR;
however, little evidence has been produced in support
of this contention. Evidence that T cells with exclusively
direct allospecificity can affect transplant rejection was
provided in a very recent study. Reconstitution of severe
combined immunodeficiency (SCID) or Rag1⫺/⫺ mice
with syngeneic CD4⫹ T cells led to rejection of MHC
class II–expressing cardiac allografts but not MHC class
II–deficient grafts. Furthermore, Rag1⫺/⫺ mice that were
also MHC class II deficient rejected allogeneic cardiac
transplants when reconstituted with CD4⫹ T cells. Since
these mice have no CD8⫹ cells and lack the capacity
for MHC class II–restricted indirect allorecognition (see
below), these results indicate that direct pathway CD4⫹
T cells were both necessary and sufficient to mediate
allograft rejection (Pietra et al., 2000).
The Indirect Pathway of Anti-MHC Allorecognition
and Transplant Rejection
The alternative pathway of allorecognition is referred to
as the indirect pathway. This results from the recognition
of allogeneic MHC molecules, predominantly MHC molecules, as peptides, presented in the context of selfMHC (Figure 2). Given that this corresponds to the manner by which T cells recognize all other nominal antigens,
the term “indirect” may be misleading; however, it
serves to contrast this mode of allorecognition with the
direct pathway. In fact, MHC peptides are quite fre-
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Figure 2. Direct and Indirect Allorecognition
(Indirect allorecognition) Alloantigens are shed from the donor cell surface or are taken up as dying allogeneic cells by host antigen-presenting
cells (e.g., immature DCs). In the latter, peptides derived from allogeneic MHC molecules are re-presented on the self-MHC molecules (black
circles), especially MHC class II, of the recipient antigen-presenting cells, much like conventional antigens. Helper cells recognizing donor
MHC class I or II peptides on responder MHC then help the formation and function of CD8⫹ CTL that directly recognize donor allogeneic MHC
molecules (e.g., by releasing IL-2 or other cytokines). (Direct allorecognition) Recipient T cells engage with complexes of intact allogeneic
MHC molecules and bound peptides (striped circles) on the surface of donor cells.

quently eluted from the peptide binding grooves of MHC
molecules (Rudensky et al., 1991; Chicz et al., 1993).
The most striking demonstration of the propensity of
MHC molecules to be presented in peptide form by other
MHC molecules involved Y-Ae, the first monoclonal antibody that was shown to be specific for an MHC-peptide
complex. This antibody sees a peptide fragment from
the H2-E␣ chain (highly conserved in homologous genes
from rat and human) presented on H2-Ab products (Rudensky et al., 1991). The corresponding MHC-peptide
complex is expressed at high levels on DCs and B cells
from strains expressing H2-Ab and H2-E but not from
strains expressing H2-Ab alone or H2-E with other H-2A
alleles. The high level of staining obtained with this antibody illustrates the capacity of MHC molecules to present MHC-derived peptides. This has also been demonstrated in the DCs of the thymic medulla, an important
site for the development of thymic or central tolerance
by negative selection.
The original proposition that a second pathway of
allorecognition exists and can contribute to transplant
rejection arose from a DC depletion experiment involving rat kidney transplantation (Lechler and Batchelor,
1982a). These studies were based on the pioneering
experiments of Lafferty and colleagues, who performed
a series of transplants using thyroid or pancreatic islet
tissues that had been depleted of bone marrow–derived
cells by in vitro culture. They noted that the depleted

grafts enjoyed prolonged if not indefinite survival (Talmage et al., 1976; Bowen et al., 1980). This highlighted
the distinction between antigenicity (the capacity to be
recognized) and immunogenicity (the capacity to induce
an effective immune response). Their interpretation of
these findings was that bone marrow–derived cells were
both antigenic and immunogenic, while the parenchymal
cells of the graft were merely antigenic. The finding in
the rat kidney model was that, in certain strain combinations in which primary kidney allografts were rapidly
rejected, retransplanted grafts that had been “parked”
in an intermediate recipient for 1 month or more under
the cover of immunosuppression were spontaneously
accepted without any exogenous immunosuppression
(Lechler and Batchelor, 1982a). The relevance of DCs
to these findings is discussed below. One of the strain
combinations in which retransplanted kidney grafts
were accepted without exogenous immunosuppression
was (AS ⫻ AUG) F1 into AS. However, if the strain combination was changed and fully allogeneic AUG donors
were used, the retransplanted grafts were invariably rejected, albeit at a slower tempo. Based on the assumption that the parenchymal tissues of the kidney were
incapable of activating direct pathway antidonor T cells,
it was proposed that a second, indirect, pathway of
allorecognition was responsible for T cell sensitization.
Since the existence of the indirect pathway was first
proposed, a large literature has accumulated illustrating
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that this pathway can cause transplant rejection (reviewed in Auchincloss and Sultan, 1996). A comprehensive series of experiments has been performed by Auchincloss and colleagues using MHC class I and II
knockout donor and recipient mice. Their most compelling evidence that the indirect pathway is sufficient to
mediate transplant rejection was the observation that
MHC class I knockout recipient mice could reject skin
grafts from MHC class II knockout donor mice (Grusby
et al., 1993). The recipient mice lacked CD8⫹ cytotoxic
T cells capable of recognizing donor MHC class I molecules directly, and the CD4⫹ T cells in the recipient
animals could only be stimulated by recognizing donor
MHC class I molecules indirectly, presented in the context of recipient MHC class II molecules.
Returning to the original experiments with donor DCdepleted kidney grafts, in the strain combinations in
which rejection occurred, the tempo was invariably
slower, with a mean rejection time of 21 versus 10 days
for DC-replete grafts. This was the basis for suggesting
that the indirect pathway might be most prominent in
later, more chronic forms of rejection. The hypothesis
that T cells with indirect antidonor allospecificity are
important drivers of chronic transplant rejection has received support from several clinical studies.
First, it appears that the strength of the direct antidonor alloresponse diminishes with time after transplantation. In renal and cardiac transplant patients, the frequencies of antidonor CD4⫹ T cells proliferating and
secreting cytokines in response to donor cells is substantially reduced compared with frequencies measured
against third-party cells (Mason et al., 1996; Hornick et
al., 1998). A similar fall in the frequencies of CD8⫹ T
cells has been documented. This is likely to reflect the
consequences of alloantigen presentation by the nonimmunogenic parenchymal cells of the transplanted tissue.
Indeed, culture of CD4⫹CD4RO⫹ T cells with HLA-mismatched, ␥-interferon-treated primary epithelial cell cultures from human thyroid or kidney induced allospecific
hyporesponsiveness (Marelli-Berg et al., 1997; Frasca
et al., 1998). If this is the correct explanation for the
decline of the direct antidonor alloresponse, the transplant-induced hyporesponsiveness should be most pronounced in the CD45RO⫹ T cell population, in that alloreactive T cells of this phenotype are the ones that can
cross the donor endothelium and enter the graft. We
have recently tested this prediction by measuring antidonor and anti-third-party frequencies in CD45RA⫹ and
CD45RO⫹ T cells at the time of transplantation and 4
months later. A significant fall in antidonor frequency
was only seen in the RO⫹ T cell fraction, in keeping with
a role for transplant parenchymal cell antigen presentation in limiting the activity of the direct pathway response
with time (Baker et al., 2001). Perhaps most significantly,
the decline in the direct response was equally pronounced in patients with classical features of chronic
rejection as in those with stable good function (Mason
et al., 1996; Hornick et al., 1998). This finding suggests
that the direct pathway of antidonor alloreactivity is not
an important driver of chronic rejection.
The second series of clinical data comes from attempts to measure the indirect pathway in patients with
established chronic rejection. Two approaches have
been taken to reveal T cells with indirect alloreactivity.

One involves offering donor MHC molecules as synthetic
peptides, thereby bypassing the need for antigen processing. Three groups have reported raised frequencies
of T cells with indirect antidonor specificity in patients
with chronic heart (Liu et al., 1996), kidney (Vella et al.,
1997), and lung (SivaSai et al., 1999) transplant rejection.
The other approach that has been used involves offering
donor antigens in the form of lysed whole cells, thereby
making no assumption as to which peptides will be recognized. Using this approach, we have detected raised
frequencies of indirect pathway T cells in patients with
but not without chronic heart transplant rejection (Hornick et al., 2000).
If the indirect pathway is critical in mediating transplant rejection, it follows that abolition of the direct pathway alone will not achieve allograft tolerance. More importantly, strategies that promote tolerance in the
indirect pathway should enhance allograft survival. One
strategy that has been employed to avoid direct pathway
sensitization is to use, as donors, animals chimeric for
recipient bone marrow. Krasinskas et al. created such
bone marrow chimeras in mice and rats. This led to
prolongation of graft survival in all cases, although the
extent of the effect varied between different strain combinations. Despite this, allograft vasculopathy, an indication of chronic rejection, occurred in all recipients
(Krasinskas et al., 2000). Although APC-depleted kidneys and skin grafts were rejected, APC-depleted islet
grafts were accepted permanently without immunosuppression. It would appear at first sight that this was
due to the lack of direct pathway stimulation; however,
Coulombe and coworkers recently showed that the tolerance in such a model is CD4⫹ T cell dependent (Coulombe et al., 1999). Since these islet grafts were essentially negative for MHC class II expression, this implied
that the tolerance was maintained through the indirect
pathway. Compelling evidence that induction of tolerance in the indirect pathway favors graft survival came
from experiments in which recipient animals were pretreated with donor MHC peptides. The peptides were
administered either intrathymically (Chowdhury et al.,
1996) or orally (Zavazava et al., 2000) or as donor peptide-pulsed recipient APCs (Ali et al., 2000). All of these
treatments induced graft prolongation. Although the
mechanisms of these strategies have not been defined,
the use of donor peptides means that the enhancement
of graft survival can only be mediated through the indirect pathway. Equally interesting is the finding, in a murine skin allograft model, that tolerance cannot be induced in the absence of the indirect pathway. In this
model, if normal MHC-mismatched skin was transplanted onto normal recipients, treatment with antiCD40L, CTLA-4-Ig, and anti-CD8 led to long-term skin
graft survival. Furthermore, the recipients became tolerant, as evidenced by the ability of their T cells to protect
a fresh skin graft from the same donor strain following
adoptive transfer. In contrast, if the response was confined to the direct pathway, due to the use of the socalled II⫺4⫹ mice as recipients (these mice express MHC
class II molecules only in the thymus and not on peripheral APC) and if the same immunosuppressive protocol
was used, all the grafts were rejected (Yamada and
Auchincloss, personal communication). This suggests
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that tolerance in the indirect pathway may be required to
inhibit direct pathway T cells and to maintain tolerance.

The Role of Donor Dendritic Cells in Transplant
Rejection or Tolerance
At face value, the contribution of DCs to transplant rejection may seem quite straightforward within this framework of direct and indirect allorecognition. Donor DCs
initiate direct pathway responses, and recipient DCs
initiate the activation of T cells with indirect allospecificity. Indeed, these were the concepts that grew out of
the original “passenger cell” observations. As outlined
above, the seminal finding was that depletion of donor
leukocytes led to prolonged allograft survival. A variety
of methods was used to deplete leukocytes, although,
at the time, reagents such as monoclonal antibodies
were not available to monitor and identify the types
of depleted cells, distinguishing, for example, between
tissue macrophages and tissue DCs. Lafferty used lowtemperature culture or culture in hyperbaric oxygen to
kill off passenger cells while preserving the viability of
the tissue parenchymal cells. He applied these techniques to thyroid and pancreatic transplants (Talmage
et al., 1976; Bowen et al., 1980). The rat kidney graft
experiments involved parking the kidney in an intermediate recipient under the cover of immunosuppression.
Support for the concept that the lack of rejection of
these retransplanted grafts was due to the loss of immunogenic donor bone marrow–derived APC came from
the finding that injection of as few as 104 donor strain
DC at the time of retransplantation led to brisk rejection
(Lechler and Batchelor, 1982a). Furthermore, if the intermediate recipient was made into a bone marrow chimera
with donor strain bone marrow after acceptance of the
primary graft, the retransplanted grafts were rejected
as promptly as the primary graft would have been in the
absence of immunosuppression (Lechler and Batchelor,
1982b).
The most intuitive interpretation of these experiments
was that the donor DC made a vital contribution to sensitization of the direct pathway and that, in their absence,
the fate of the tissue depended upon the strength of
the indirect pathway, which would be predicted to be
under classical Ir gene control. However, the assumptions underlying this interpretation were not tested. For
example, it would be predicted that a DC-depleted graft
would cause little amplification of the direct response,
while a DC-replete graft would induce an increased frequency of T cells with direct antidonor allospecificity.
Measurement of direct and indirect pathway sensitization was not undertaken in these studies.
In apparent contradiction to the classical passenger
cell experiments, a series of groups have reported that
depletion of donor bone marrow–derived cells prevents
the induction of transplantation tolerance. For example,
Cuturi noted that depletion of passenger leukocytes
from rat donor heart allografts reversed the beneficial
effects of donor-specific blood transfusion. Furthermore, tolerance was reestablished if donor-type DCs
were cotransferred at the time of transplantation of APCdepleted cardiac grafts (Josien et al., 1998). Similarly,
using rat strain combinations in which liver allografts are

spontaneously accepted, without immunosuppression,
donor irradiation led to liver graft rejection (Sun et al.,
1995). Although the possibility was not fully excluded
that donor irradiation modified the graft in some deleterious way—altering vascular permeability, for example—
these results probably indicate a need for donor leukocytes in the induction of tolerance.
Given the key role of the indirect pathway of allorecognition in transplant rejection and in transplantation tolerance, these results do not necessarily challenge the
importance of the donor DC in priming direct pathway
T cells. Rather, they may highlight the possibility that
the donor DC, due to its propensity for migrating to
draining lymph nodes, can provide a source of donor
antigen, in the lymph node, for the induction of tolerance
in T cells with indirect allospecificity. Support for this
concept is provided by further experiments using the
Y-Ae monocloncal antibody to monitor the processing
and presentation of H2-E␣ in vivo. When H2-E-bearing
DCs were injected into H2-Ab recipients, within 2 days
most of the recipient DCs in the draining lymph node
became reactive with Y-Ae. The number of donor cells
in the lymph node was very much smaller than the number of recipient DCs that had processed the donor H2-E
(Inaba et al., 1998). This result implies that, when migratory donor DCs die upon reaching the lymph node, they
are phagocytosed and processed by resident recipient
DCs. However, these experiments have yet to elucidate
if cross-presentation by DCs leads to immunity (crosspriming) or specific unresponsiveness (cross-tolerance)
(Figure 3).
This interpretation of the role of the donor DC does
not immediately resolve the conflicting data as to
whether they are “friends” or “foes” of the transplanted
tissue. However, in the models where donor leukocytes
are required for the expression of tolerance induced by
prior antigen exposure, donor DCs may be required to
amplify indirect pathway regulatory cells primed by the
earlier antigen treatment. In the case of spontaneously
accepted liver grafts, the explanation may lie with the
particular properties of Kuppfer cells, a liver-specific
population of leukocytes, or, indeed, with the tolerancepromoting effects of the liver itself. It is also possible
that distinct subsets of tolerogenic DCs exist and that
they are differentially distributed in different organs.
Another set of data that relate to the role of donor DC
in transplant immunity concerns the phenomenon of
donor microchimerism, as observed by Starzl and coworkers. They have described the detection of donor
cells in a variety of peripheral sites and in the thymus
of recipient animals and in patients, following organ
transplantation. This has been most pronounced in recipients of liver grafts, not surprisingly, due to the larger
load of bone marrow–derived cells cotransplanted with
a liver. It has been argued that the seeding of recipient
tissues with such donor cells is instrumental in the induction of donor-specific tolerance for donor antigens
(Starzl et al., 1996). Two major issues remain unresolved
regarding this hypothesis. First, it is unclear whether the
persistence of donor leukocytes in tolerant recipients
represents cause or effect. If the recipient has become
tolerant to donor alloantigens, this is likely to favor the
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Figure 3. Roles of Donor and Recipient Dendritic Cells in Direct and Indirect Allorecognition
(1) The graft contains donor DCs (black) as well as recipient immature DCs (white).
(2) Recipient DCs that have captured antigens from the graft (e.g., dying cells) enter the lymph, much like donor graft-derived DCs.
(3) In the recipient lymph nodes, donor DCs and recipient DCs can stimulate the direct and indirect pathways of allorecognition. In addition,
donor DCs can die in the lymph node, and their MHC products can be processed widely by the recipient DCs.
(4) As a result of (3), many more recipient DCs in the lymph nodes are able to capture and present donor peptides to indirect allospecific
recipient T cells.

persistence of long-lived donor cells that would otherwise be destroyed. Second, it is not clear whether microchimerism is a mechanism for the induction of tolerance in the direct or the indirect pathway.
The Role of Recipient Dendritic Cells in Transplant
Rejection or Tolerance
There can be little doubt that a major contribution of
the recipient DC to transplant rejection is by sensitizing
T cells with indirect antidonor specificity. A variety of
experimental models have been designed to examine
the pathways whereby DCs could stimulate the indirect
pathway of rejection. The mechanism that leads to indirect allosensitization involves the internalization and
processing of proteins from dead or dying donor cells
and subsequent presentation by the MHC products of
a recipient DC. Immature DCs are able to phagocytose
apoptotic and necrotic cells and then present peptides
on both MHC class I and II products (Albert et al., 1998;
Inaba et al., 1998; Sauter et al., 2000). Successful presentation requires that the DCs mature after the initial
uptake step (Albert et al., 1998; Inaba et al., 1998). Monocytes are, if anything, more phagocytic than mature DCs
but seem to thoroughly degrade the ingested proteins
rather than resurrect peptides from the dead cells (Albert
et al., 1998). B cells, to date, are poor at cross-presentation (Munz et al., 2000). This may in part be due to limited
phagocytic activity, but studies with different antigenpresenting cell lines (Regnault et al., 1999; Rodriguez et

al., 1999) suggest that DCs are peculiarly differentiated
to cross-present antigens on MHC class I.
The processing of MHC class II donor alloantigens
has primarily been studied using the Y-Ae antibody specific for the H2-Ab-E␣ peptide complex as described
above. Dead H2-E⫹ donor B cells were fed to DCs that
expressed H2-Ab, and indirect presentation was monitored by the development of the epitope recognized by
the Y-Ae antibody. The H2-Ab DCs became reactive with
Y-Ae, and the processing was sensitive to a blockade
of proteolysis with ammonium chloride. The indirect
pathway was unusually efficient in DCs. If one estimated
the amount of H2-E protein in the dead cells that were
offered to the DCs and compared this to the amount of
H2-E peptide giving rise to the same amount of MHC
peptide complex (Y-Ae epitope), the dead cells were
several thousand times more effective as a source of
antigen (Inaba et al., 1998). Interestingly, the sequence
of the relevant H2-E peptide is conserved in HLA-DR␣,
and human B-LCL could also be processed by mouse
DCs to form the Y-Ae epitope. In ongoing experiments,
DCs are proving to be the main cell type in spleen that
cross-presents H2-E protein when dead B cells are injected intravenously. Likewise, a recent report shows
that DCs are the main cell type that cross-presents cellassociated donor proteins (in this case, ovalbumin) on
MHC class I products (den Haan et al., 2000). The implication of these experiments is that, whenever dead cells
are cleared from a graft via the blood or lymph, the MHC
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products from the dead cells might undergo efficient
processing and presentation by the recipient DCs.
As stated earlier, a tissue DC requires a maturation
signal in order to become immunogenic. Such signals
can be provided by invading pathogens or tissue inflammation or injury (Janeway, 1992; Matzinger, 1994). One
difficulty with this “danger” theory is that it does not
resolve a new view of the self–nonself dilemma that
has emerged from studies of DC maturation. During
infection—when DCs phagocytose dying infected cells,
as well as proteins, in the infected environment, such
as the lung or gut—how do the DCs selectively present
microbial proteins and not proteins from dying self-tissue or the environment? For this reason, it has been
proposed (Steinman et al., 2000) that, in the steady state,
DCs have the capacity to tolerize the T cell repertoire
peripherally to those self and environmental proteins
that are readily processed. These proteins would be
captured during the traffic of DCs through the tissues
and lymph, especially from cells dying through the normal process of cell turnover. Uptake of dying intestinal
epithelial cells has been observed in DCs trafficking in
rat mesenteric lymph (Huang et al., 2000), and a subset
of DCs in the lymph seems to be preferentially involved.
Possibly, a subset of DCs, as proposed for CD8⫹ mouse
spleen DCs by Shortman (Kronin et al., 1996), have a
tolerizing or regulatory role. Likewise, several laboratories (Forster and Lieberam, 1996; Kurts et al., 1997a;
Adler et al., 1998; Morgan et al., 1999) have shown that
bone marrow–derived cells in the lymph node (possibly
DCs) can tolerize T cells, by deletion or anergy, to antigens cross-presented from nonhematopoietic cells.
This tolerance is delicate. In the experiments of Kurts
et al., an infusion of CD4⫹ helper cells broke the tolerance of CD8⫹ T cells (Kurts et al., 1997b). In a recent
study by Bingaman et al., where a large number of T
cells or thymocytes were introduced into nude animals
bearing well-healed allografts, rejection was readily induced in the ostensible absence of danger (Bingaman
et al., 2000). Perhaps these data can be reconciled by
proposing that DCs in the steady state, in the absence
of maturation stimuli, only have the capacity to silence
and/or regulate small numbers of low-affinity T cells
specific for self-peptides. If the number of T cells exceeds a certain limit (as in Kurts’ experiments) or are
of higher affinity (as in Bingaman’s experiments), the
tolerogenic effects of immature DCs may be overridden.
The implication of all of these observations is that
the indirect pathway of allorecognition is driven by the
efficient functioning of normal antigen presentation
pathways. This may explain, in part, why chronic rejection
is so refractory to conventional immunosuppression.

Dendritic Cells and Transplantation Tolerance
Returning to the question posed by the title of this review, it seems that the DC is almost inevitably a foe in
the context of tissue transplantation. The donor DC is
implicated as a foe by the passenger cell depletion experiments conducted with endocrine and kidney grafts.
The recipient DC also appears to be responsible for
priming and maintaining the indirect alloresponse.

Based on current knowledge of DC biology, this is predictable; surgeons are “dangerous,” and the trauma of
surgery and ischemia–reperfusion injury will invariably
provide the maturation signals that tissue DC may require in order to migrate and induce T cell activation.
The possible exception to this generalization is the liver,
based on the irradiation experiments mentioned above.
Nonetheless, it is not clear that elimination/inactivation
of DCs is responsible for the beneficial effects of donor
irradiation, and Kupffer cells and sinusoidal lining cells
(Limmer et al., 2000) may well be important contributors
to these events.
However, new research suggests that circumstances
can be created in which DCs can be considered as
friends capable of inducing peripheral tolerance. As
summarized above, donor DCs may be required for the
development of tolerance induced by donor antigen pretreatment (Josien et al., 1998), and exposure to immature
DCs can prolong graft survival.
Thomson’s group has explored this possibility in detail. They injected mice with allogeneic DCs, but they
did so at the immature stage of development. A modest
prolongation of graft survival was observed, and this
was specific, since it was not seen following a challenge
with third-party grafts (Fu et al., 1996). In experiments
where DCs have been used to immunize mice with nominal antigens, mature DCs have been much more immunogenic than immature DCs (Stumbles et al., 1998; Inaba
et al., 2000; Schuurhuis et al., 2000). However, the studies in transplantation raised the possibility that immature
DCs were not simply ignored but could be actively tolerogenic. Likewise, studies on the presentation of self
(Forster and Lieberam, 1996; Kurts et al., 1997a; Adler
et al., 1998; Morgan et al., 1999) antigens in mice have
shown that bone marrow–derived cells are capable of
mediating peripheral tolerance by cross-presentation of
self or tumor antigens. In these experiments, self- and
tumor-reactive CD4⫹ and CD8⫹ T cells could be deleted
(Kurts et al., 1997a) or anergized (Forster and Lieberam,
1996; Adler et al., 1998) upon encounter of antigens in
the steady state, under “noninflammatory” conditions.
An alternative mechanism for transplantation tolerance has emerged from in vitro studies of the MLR,
using DCs at an immature stage of differentiation. Again,
it has been repeatedly observed that immature DCs are
weak stimulators of the MLR, but recent data have significantly extended these findings (Jonuleit et al., 2000).
Alloreactive CD4⫹ cells of the Th1 type developed when
mature DCs were used as stimulators. However, when
immature DCs from the same donor were used to stimulate the same allogeneic T cells, the T cells proliferated
minimally, lost the capacity to be stimulated by mature
DCs, and, importantly, would significantly inhibit the responses of alloreactive Th1 cells to mature DCs. Therefore, T cells induced with immature allogeneic DCs had
a regulatory function and also produced IL-10, as has
been seen with cloned T regulatory cells. The mechanism of regulation in the Jonuleit et al. study also involved cell–cell contact.
A second in vivo study of regulation by immature DCs
was just reported by Dhodapkar et al., using influenza
viral peptide as a nominal antigen. They had shown
that, when volunteers were given the peptide in saline,
antigen-reactive CD8⫹ T cells did not expand, but, when
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stimulated with peptide-pulsed mature DCs given subcutaneously, the CD8⫹ T cells responded rapidly. In contrast, when immature DCs were used in two individuals,
the peptide-reactive CD8⫹ T cells were silenced in terms
of IFN-␥ production and cytolytic function, but antigenspecific IL-10-producing CD8⫹ T cells were now detected (Dhodapkar et al., 2001). This silencing of CD8⫹
effectors by immature DCs was specific for the influenza
peptide on the DCs, since other cytomegalovirus (CMV)specific CD8⫹ T cells were unperturbed.
These studies with human DCs have uncovered a potential role of immature DCs in the induction of regulatory T cells. The findings suggest that the injection of
immature DCs, away from the site of the graft and therefore away from maturing inflammatory signals, may actively regulate alloreactivity. Two types of regulatory T
cells, possibly related, are under study: the Tr1 regulatory cells that produce high levels of IL-10 (Groux et al.,
1997) and the CD4⫹CD25⫹ suppressors for autoimmunity (reviewed in Shevach, 2000). These populations
were both discovered in the investigation of in vivo tolerance. Tr1 cells were first appreciated in the setting of
SCID bone marrow transplant recipients who were resistant to graft versus host (GVH), while CD4⫹CD25⫹ suppressors were identified as CD5 high, CD45RB, and RC
low suppressors of several autoimmune diseases in rodents (Sakaguchi and Sakaguchi, 1990; Fowell and Mason, 1993).

Manipulating Dendritic Cells to Promote
Tolerance Induction
The risk in using immature DC for tolerance induction
is that they may inadvertently receive maturation signals
in vivo and have the opposite effect to that intended.
One solution to this problem is to manipulate the DC in
vitro in order to inhibit its immunogenicity and potentiate
its capacity to induce tolerance. There is both in vitro
and in vivo evidence in support of this approach. For
example, genetically engineered DC that constitutively
express viral IL-10 (Takayama et al., 1998), TGF-␤ (Lee et
al., 1998), FasL (Min et al., 2000), or CTLA-4-Ig (O’Rourke
et al., 2000) can induce alloantigen-specific T cell hyporesponsiveness and enhance the survival of allografts
in nonimmunosuppressed recipients. Other strategies
that have been successful in generating “tolerogenic”
DC include corticosteroids (Rea et al., 2000), vitamin D3
(Penna and Adorini, 2000), and culture with a suboptimal
dose of GM-CSF (Lutz et al., 2000). The common features of these tolerogenic DCs are the reduced expression of costimulatory molecules, in particular, CD86.
The expression of both MHC class I and II molecules,
maturation markers such as CD83, and adhesion molecules are also often downregulated. Thus, one possible
explanation of their tolerogenic potential is the induction
of donor-specific anergy of the direct pathway antidonor
T cells as a result of antigen recognition in the absence
of costimulatory signals. Furthermore, the tolerogenic
effect of these manipulated DC may not be limited to the
direct pathway. Finally, since many of these “designer”
tolerogenic DC carry immunoregulatory substances
(such as IL-10, TGF-␤, and CTLA-4-Ig), this may have
more generalized effects on other cell types.

Summary
The existence of two sets of dendritic cells in transplantation (of donor and recipient origin) poses unique
problems in alloimmunity and tolerance. Donor DCs are
potent stimulators of the direct pathway, in which recipient T cells respond to peptides presented on donor MHC
products or to the donor MHC molecules themselves.
Reduced DC function in the direct pathway is used to
explain the acceptance of certain allografts that have
been depleted of passenger leukocytes. Reciprocally,
purified donor DCs powerfully stimulate the rejection of
these grafts as well as the mixed leukocyte reaction by
purified allogeneic T cells in culture. Donor DCs also can
act as specialized antigen transport vehicles in crosspriming for the indirect pathway. Here, recipient DCs
process MHC molecules from the donor. The indirect
pathway of rejection is actually the rule for passenger
leukocyte-depleted grafts. Furthermore, the indirect
pathway seems to be the dominant alloresponse detected in long-term graft recipients, both in experimental
models and clinical transplantation, particularly in those
with chronic rejection. The stimulatory function of DCs
in both direct and indirect pathways is regulated by their
maturation in response to inflammatory stimuli, especially those delivered via IL-1, TNF, and Toll receptor
families. Since the normal function of DCs is to generate
immunity against invading pathogens, the indirect response to peptides continually derived from the allogeneic MHC molecules in a tissue allograft (a surgically
introduced “pathogen” because of the associated inflammation and necrosis) may be more difficult to silence. However, in addition to their allostimulatory role,
immature or in vitro–manipulated DCs also have the
potential to downregulate direct and indirect antidonor
responses through a variety of mechanisms. Intriguing
new evidence shows that immature DCs can actively
induce regulatory T cells. Given the probable role of
the indirect pathway in driving chronic rejection, the
induction of T cell tolerance (deletion, anergy, and regulation), especially in those T cells with indirect antidonor
allospecificity, by the injection of immature DCs pretransplant, could serve as a critical therapeutic strategy.
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